Patients with diabetes with and without sodium-glucose cotransporter-2 inhibitors use with incident cancer risk

• Published in: Journal of diabetes and its complications Vol. 37; no. 5; p. 108468
• Main Authors: Hu, Wei-Syun, Lin, Cheng-Li
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.05.2023; Elsevier Limited
• Subjects: Age groups; Anticoagulants; Breast cancer; Cancer; Cardiovascular disease; Chronic obstructive pulmonary disease; Colorectal cancer; Coronary vessels; Diabetes; Diabetes mellitus; Diabetes Mellitus, Type 2 - complications; Diabetes Mellitus, Type 2 - drug therapy; Diabetes Mellitus, Type 2 - epidemiology; Esophagus; Glucose; Heart failure; Humans; Hypertension; Insulin; Kidney cancer; Lipids; Liver cancer; Lung cancer; Metabolism; National health insurance; Neoplasms - chemically induced; Neoplasms - epidemiology; Patients; Prostate cancer; Risk; Sodium; Sodium-glucose cotransporter-2 inhibitors; Sodium-Glucose Transporter 2 Inhibitors - adverse effects; Statistical analysis; Thyroid cancer; Vein & artery diseases; Taiwan; Sodium-glucose cotransporter-2 inhibitors; Diabetes mellitus; Cancer
• ISSN: 1056-8727; 1873-460X; 1873-460X
• DOI: 10.1016/j.jdiacomp.2023.108468

The study compared the incidence of cancer between patients with diabetes with and without sodium-glucose cotransporter-2 (SGLT2) inhibitors use. This study identified a non-SGLT2 inhibitor cohort of 325,989 patients and a SGLT2 inhibitor cohort of 325,990 patients. The primary interest of this study was the occurrence of cancer. Hazard ratios (HRs) and 95 % confidence intervals (CIs) were estimated using Cox proportional hazard models. Patients receiving SGLT2 inhibitors (adjusted HR = 0.79, 95 % CI = 0.76–0.83) had a significantly lower risk of developing cancer than patients without receiving SGLT2 inhibitors. The results demonstrated that patients with diabetes receiving SGLT2 inhibitors had a significantly lower risk of cancer. •The study compared the incidence of cancer between patients with diabetes with and without SGLT2 inhibitors use in Taiwan between 2016-2019.•The strength of this study was from a large dataset.•Out study showed that patients with diabetes who took SGLT2 inhibitors had a significantly lower risk of cancer.